Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
Researchers are conducting a study to explore a new potential treatment for a type of lung cancer known as non-small cell lung cancer. This treatment is called MYTX-011 and is a specific kind of drug designed to target cancer cells. This is an early-stage study, meaning it's among the first times this treatment is being given to people. The main goals are to check if MYTX-011 is safe, to understand any side effects it might have, and to find the most effective dose. The study will also look at how the treatment works against the cancer. It's open to adults aged 18 and over, and both men and women can participate.
At a glance
What is this study about?
This research study is focused on finding new ways to treat non-small cell lung cancer, which is the most common type of lung cancer. The specific treatment being studied is called MYTX-011. This isn't a standard chemotherapy; it's a newer type of medicine known as an 'antibody-drug conjugate.' Think of it like a guided missile: the 'antibody' part is designed to specifically find and attach to cancer cells, and then the 'drug' part is delivered directly to those cells, aiming to cause less harm to healthy cells.
This study is in its early stages, known as Phase I and Phase II. This means it's one of the first times this new treatment will be given to people. The main reason for starting with these phases is to carefully check if the treatment is safe for patients, to understand any possible side effects, and to figure out what dose works best without causing too many problems. It's a crucial step in developing any new medicine.
By taking part, individuals could help doctors learn important information about MYTX-011. This knowledge could potentially lead to new and better treatments for non-small cell lung cancer in the future. Even if an individual doesn't directly benefit, their participation could make a big difference for other patients down the line.
Key takeaways
- New study for non-small cell lung cancer using MYTX-011.
- MYTX-011 is an 'antibody-drug conjugate' – a targeted treatment.
- This is an early-stage trial (Phase I/II) to check safety and find the best dose.
- Open to adults aged 18 and over, both men and women.
- Participation involves regular hospital visits and monitoring.
- You can withdraw from the study at any time.
Who may be eligible?
To join this study, people need to be at least 18 years old. There's no upper age limit mentioned, so older adults could also be considered. The study is open to both men and women.
There will be other important health checks and medical requirements that help the study team decide if this treatment is suitable and safe for you. These can include your specific type of lung cancer, any other health conditions you might have, and previous treatments you've received. The research team will review all of your medical information to see if you meet all the criteria.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you at least 18 years old?
- Have you been diagnosed with non-small cell lung cancer?
- Are you able to attend regular hospital appointments?
- Are you comfortable with receiving a new, experimental treatment?
- Have you discussed your overall health with your doctor?
What does participation involve?
If you decide to join this study, you'll have regular hospital visits for check-ups, tests, and to receive your study medication. These visits will help doctors monitor your health, see how the treatment is affecting you, and look for any side effects. You'll likely have blood tests, scans, and other medical examinations at these appointments.
The specific drug, MYTX-011, will be given to you according to the study plan. You'll be closely monitored during and after your treatment. The study will also involve follow-up appointments after your treatment ends to continue checking on your health and any long-term effects. The total duration of your involvement could vary, but the study team will explain the full schedule to you before you agree to participate.
Potential risks and benefits
Locations (2)
- —UnverifiedFrance
- —UnverifiedSpain
Common questions
What is an antibody-drug conjugate?
It's a new type of medicine that's designed to deliver a cancer-fighting drug directly to cancer cells, like a guided missile, trying to avoid harming healthy cells as much as possible.
What does Phase I and Phase II mean?
These are early stages of clinical trials. Phase I mainly checks if a new treatment is safe and finds the best dose. Phase II looks more closely at how well it works and continues to monitor safety.
Will I definitely get the new drug?
Yes, in this type of study, all participants receive the study drug. There isn't a placebo group in this particular trial phase.
What kind of tests will I have?
You'll likely have regular blood tests, physical exams, and possibly scans (like CT or MRI) to check your health and how the treatment is affecting your cancer.
Can I leave the study if I change my mind?
Absolutely. You can choose to leave the study at any time, for any reason, and it won't affect the care you receive from your doctors.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.